FIELD: medicine.
SUBSTANCE: presence of beta-adrenergic blocker is determined among the drugs recommended at release, and/or within a year after myocardial infarction, hospitalization in a specialized hospital. A prior myocardial infarction is determined in the history, as well as carbohydrate metabolism disorders of various nature (impaired glucose tolerance, impaired fasting glucose or type 2 diabetes) by survey or medical records analysis. The probability of death (p) is calculated according to the original formula. With a value of p ≥0.6, an adverse post-infarction period is predicted.
EFFECT: method allows to identify individuals with unfavorable course of postinfarction period and to carry out the corresponding correction of diagnostic and treatment strategies for patients of working age.
1 tbl, 2 ex
